New Genetic Variants Identified for Bloom Syndrome
|
By LabMedica International staff writers Posted on 24 Jun 2015 |

Image: The face of a patient with Bloom syndrome or congenital telangiectatic erythema, a rare autosomal recessive disorder (Photo courtesy of Dr. Amira M. Elbendary).
For many diseases, testing is limited to detecting only the most common variants that are associated with a particular ethnicity, such as Ashkenazi Jews, who are known to have genes that make them susceptible to a variety of diseases.
Among those disease affecting Ashkenazi Jews is the rare condition Bloom syndrome, which causes varying degrees of immunodeficiency as well as sun sensitivity, telangiectatic erythema of the face, and stunted growth.
Scientists at the molecular information company Good Start Genetics, Inc. (Cambridge, MA, USA) conducted an extensive literature review and examining sequence-based, laboratory and bioinformatics evidence. Study participants were 22,864 ethnically diverse individuals referred by fertility clinics from across the USA for routine carrier screening between April 2012 and February 2014. Informed consent processes were followed for each patient.
The investigators identified 50 genetic variants of the gene for Bloom syndrome (BLM) that it deemed pathogenic, or associated with Bloom syndrome. The literature review turned up 76 variants, but some were excluded from the test's list of pathogenic sequences following further scrutiny by the scientists. During screening, they detected 39 carriers of 11 different mutations that it had previously identified as pathogenic. Using a subset of the data, the company found the carrier rate to be 1/510 subjects, consistent with the expected ratio based on prior knowledge.
The team identified 16 novel "truncating" variants that can be identified as pathogenic by their genetic sequence alone, and do not require laboratory experiments or statistical evidence to prove their association with the disease. More than a quarter of the carriers (28%) had one of the previously unidentified truncating genetic variants. About 40% of all carriers of Bloom syndrome genes had a known pathogenic variant that, to their knowledge, that was not included in any other commercial carrier screening test.
The authors concluded that their data indicate that using a comprehensive panel of rigorously evaluated variants for carrier screening a pan-ethnic population provides major advantages in terms of increased rates of carrier detection. Limited genotyping panels would have missed the carrier status of many of the individuals they identified because they were not carriers of the major ethnically specific common variants. The study was published online on April 23, 2015, in the journal Molecular Genetics & Genomic Medicine.
Related Links:
Good Start Genetics Inc.
Among those disease affecting Ashkenazi Jews is the rare condition Bloom syndrome, which causes varying degrees of immunodeficiency as well as sun sensitivity, telangiectatic erythema of the face, and stunted growth.
Scientists at the molecular information company Good Start Genetics, Inc. (Cambridge, MA, USA) conducted an extensive literature review and examining sequence-based, laboratory and bioinformatics evidence. Study participants were 22,864 ethnically diverse individuals referred by fertility clinics from across the USA for routine carrier screening between April 2012 and February 2014. Informed consent processes were followed for each patient.
The investigators identified 50 genetic variants of the gene for Bloom syndrome (BLM) that it deemed pathogenic, or associated with Bloom syndrome. The literature review turned up 76 variants, but some were excluded from the test's list of pathogenic sequences following further scrutiny by the scientists. During screening, they detected 39 carriers of 11 different mutations that it had previously identified as pathogenic. Using a subset of the data, the company found the carrier rate to be 1/510 subjects, consistent with the expected ratio based on prior knowledge.
The team identified 16 novel "truncating" variants that can be identified as pathogenic by their genetic sequence alone, and do not require laboratory experiments or statistical evidence to prove their association with the disease. More than a quarter of the carriers (28%) had one of the previously unidentified truncating genetic variants. About 40% of all carriers of Bloom syndrome genes had a known pathogenic variant that, to their knowledge, that was not included in any other commercial carrier screening test.
The authors concluded that their data indicate that using a comprehensive panel of rigorously evaluated variants for carrier screening a pan-ethnic population provides major advantages in terms of increased rates of carrier detection. Limited genotyping panels would have missed the carrier status of many of the individuals they identified because they were not carriers of the major ethnically specific common variants. The study was published online on April 23, 2015, in the journal Molecular Genetics & Genomic Medicine.
Related Links:
Good Start Genetics Inc.
Latest Molecular Diagnostics News
- FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling
- Microbial Saliva Test Could Help Triage Esophageal Cancer Risk
- Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
- Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
- Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
- New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy
- Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
- FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
- ctDNA Blood Test Could Help Guide Radiotherapy in Patients with Limited Metastases
- FDA-Approved MRD Blood Test Guides Adjuvant Bladder Cancer Therapy
- Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer
- Tumor Genomic Profiling Identifies High-Risk Gallbladder Cancer
- Novel Algorithm Improves Detection of B-ALL Gene Fusions
- Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample
- Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer
- Genome Sequencing Uncovers Hidden Genetic Risks in Healthy Adults
Channels
Clinical Chemistry
view channel
New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage and remains one of the most lethal solid tumors. Clinicians commonly use serum carbohydrate antigen 19-9 (CA19-9) to... Read more
Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
Psychosis commonly emerges in adolescence or early adulthood and can severely disrupt social and occupational functioning. Hallucinations, delusions, and disorganized thinking often evolve gradually, hindering... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
New AMR Assay Supports Rapid Infection Control Screening in Hospitals
As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more
Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
Bulk RNA sequencing is increasingly used to study tumor biology, but standard analyses often reduce results to gene-level summaries that miss important transcript variants and mutation patterns.... Read more








